Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This study is a single-arm, open-label, phase II study, comparing the efficacy and safety of
pyrotinib plus trastuzumab and aromatase inhibitors, in the treatment of HR (hormone
receptor)+/HER2 (human epidermal growth factor receptor 2) + MBC and inoperable LABC
patients.